Maria Castaldi1, Geena George2, Christy Stoller2, Afshin Parsikia3, John McNelis4. 1. Department of Surgery, Albert Einstein College of Medicine, Westchester Medical Center, Valhalla, NY, USA. 2. Department of Surgery, Westchester Medical Center, Valhalla, NY, USA. 3. Department of Surgery, Jacobi Medical Center, Bronx, NY, USA. 4. Department of Surgery, Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA.
Abstract
INTRODUCTION: Breast cancer is a hypercoagulable state and predisposes patients to venous thromboembolism (VTE). We sought to determine independent risk factors for VTE post-surgical treatment for breast cancer using a national risk adjusted database. METHODS: Participant Use Data Files in the National Surgical Quality Improvement Program database from 2012 to 2016 were studied. Female patients with invasive and in situ breast cancer that underwent either mastectomy with immediate breast reconstruction, autologous or implant-based, or lumpectomy were identified with current procedural terminology and International Classification of Diseases-9 codes. Venous thromboembolism was defined as occurrence of deep vein thrombosis or pulmonary embolism. Non-VTE and VTE groups were compared and statistical differences were addressed through propensity score weighting. The balance of the model was checked with comparing standardized differences before and after weighting. Multivariate logistic regression was used to determine independent predictors of VTE. RESULTS: A total of 137 449 procedures were identified. After applying exclusion criteria, 40 986 lumpectomies and 35 909 mastectomies remained for the analysis (n = 76 895). Venous thromboembolism was found in 172/76 895 patients (0.2%). In the weighted data set, mastectomy, BMI> 35 and length of stay >3 days were predictors of VTE. The greatest odds ratio (OR) was observed with mastectomy with immediate autologous breast reconstruction (OR = 8.792, P < .001; 95% CI: 3.618-21.367). CONCLUSION: Autologous breast reconstruction was associated with highest risk of VTE. Hospital LOS >3 days, BMI >35, and general anesthesia also increase odds of developing VTE. These variables are predisposing factors that need to be considered in patients undergoing surgical treatment for breast cancer.
INTRODUCTION: Breast cancer is a hypercoagulable state and predisposes patients to venous thromboembolism (VTE). We sought to determine independent risk factors for VTE post-surgical treatment for breast cancer using a national risk adjusted database. METHODS: Participant Use Data Files in the National Surgical Quality Improvement Program database from 2012 to 2016 were studied. Female patients with invasive and in situ breast cancer that underwent either mastectomy with immediate breast reconstruction, autologous or implant-based, or lumpectomy were identified with current procedural terminology and International Classification of Diseases-9 codes. Venous thromboembolism was defined as occurrence of deep vein thrombosis or pulmonary embolism. Non-VTE and VTE groups were compared and statistical differences were addressed through propensity score weighting. The balance of the model was checked with comparing standardized differences before and after weighting. Multivariate logistic regression was used to determine independent predictors of VTE. RESULTS: A total of 137 449 procedures were identified. After applying exclusion criteria, 40 986 lumpectomies and 35 909 mastectomies remained for the analysis (n = 76 895). Venous thromboembolism was found in 172/76 895 patients (0.2%). In the weighted data set, mastectomy, BMI> 35 and length of stay >3 days were predictors of VTE. The greatest odds ratio (OR) was observed with mastectomy with immediate autologous breast reconstruction (OR = 8.792, P < .001; 95% CI: 3.618-21.367). CONCLUSION: Autologous breast reconstruction was associated with highest risk of VTE. Hospital LOS >3 days, BMI >35, and general anesthesia also increase odds of developing VTE. These variables are predisposing factors that need to be considered in patients undergoing surgical treatment for breast cancer.
Authors: Jenna K Lovely; Sharon A Nehring; Judy C Boughey; Amy C Degnim; Rajakumar Donthi; William Scott Harmsen; James W Jakub Journal: Ann Surg Oncol Date: 2012-07-21 Impact factor: 5.344
Authors: B Fisher; J Dignam; N Wolmark; A DeCillis; B Emir; D L Wickerham; J Bryant; N V Dimitrov; N Abramson; J N Atkins; H Shibata; L Deschenes; R G Margolese Journal: J Natl Cancer Inst Date: 1997-11-19 Impact factor: 13.506
Authors: Brian H Tran; T JoAnna Nguyen; Brian H Hwang; Evan N Vidar; Gabrielle B Davis; Linda S Chan; Karen Woo; Alex K Wong Journal: Breast Date: 2013-05-18 Impact factor: 4.380